FDA warned Mel Honey US that its Jimerito (Melipona) Honey eye drops are an unapproved new drug.
What happened
FDA reviewed the company's website in June 2025 and its Instagram account, which directs consumers to the website. FDA found the company offered "Jimerito (Melipona) Honey" for sale with claims that it treats eye infections, cataracts, and dry eyes and promotes eye health. FDA determined the product is an unapproved new drug and is not generally recognized as safe and effective.
What FDA found
The product is a drug because the company's website and Instagram say it treats eye infections, cataracts, and dry eyes and affects eye health.
FD&C Act section 201(g)(1), 21 U.S.C. 321(g)(1)The product is a new drug because it is not generally recognized as safe and effective for those uses.
FD&C Act section 201(p), 21 U.S.C. 321(p)The product is an unapproved new drug because there is no FDA-approved application for it.
FD&C Act section 505(a), 21 U.S.C. 355(a)Selling or shipping the product in interstate commerce violates the FD&C Act.
FD&C Act sections 301(d) and 505(a), 21 U.S.C. 331(d) and 355(a)
What FDA wants
FDA asks the company to notify it in writing within fifteen working days of receipt of specific steps taken to correct the violations, with explanations and supporting documents, or to provide reasoning and evidence if it believes the product is not in violation.
Who should pay attention
- sellers of honey-based eye products
- companies making unapproved ophthalmic remedies
- brands using social media health claims
This is a summary. Read the original letter on fda.gov.